Disease · MONDO_0019613

non-functioning pituitary adenoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. non-functioning pituitary adenoma. Diseases, record MONDO_0019613. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019613

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: non-functioning pituitary adenoma; Open Targets
Open Targets ID: MONDO_0019613; Open Targets
Other names: NFPA, functionless adenoma of pituitary, functionless adenoma of pituitary gland, functionless adenoma of the pituitary, functionless adenoma of the pituitary gland, functionless pituitary adenoma, functionless pituitary gland adenoma, non-functioning adenoma of pituitary, non-functioning adenoma of pituitary gland, non-functioning adenoma of the pituitary, non-functioning adenoma of the pituitary gland, non-functioning pituitary gland adenoma, non-secretory adenoma of pituitary, non-secretory adenoma of pituitary gland, non-secretory adenoma of the pituitary, non-secretory adenoma of the pituitary gland, non-secretory pituitary adenoma, non-secretory pituitary gland adenoma, nonfunctional pituitary gland adenoma, silent pituitary gland adenoma; Open Targets
Disease Ontology: DOID:5715; Disease Ontology
NCI Thesaurus: C4348; NCI Thesaurus
Orphanet: ORPHA:91349; Orphanet
Highest stage of its drugs: Phase 3, for 1 of its 3 drugs, from ClinicalTrials.gov; Open Targets

Drugs3

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CABERGOLINE	CHEMBL1201087	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
PASIREOTIDE	CHEMBL3349607	Protein	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
ONZIGOLIDE	CHEMBL4650342		Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets5

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
DRD2	D(2) dopamine receptor	2	Dopamine D2 receptor agonist	Phase 3	https://conductscience.org/library/genes/1813	Drugs and targets
SSTR2	Somatostatin receptor type 2	2	Somatostatin receptor 2 agonist	Phase 2/3	https://conductscience.org/library/genes/6752	Drugs and targets
SSTR5	Somatostatin receptor type 5	2	Somatostatin receptor 5 agonist	Phase 2/3	https://conductscience.org/library/genes/6755	Drugs and targets
SSTR1	Somatostatin receptor type 1	1	Somatostatin receptor 1 agonist	Phase 2/3	https://conductscience.org/library/genes/6751	Drugs and targets
SSTR3	Somatostatin receptor type 3	1	Somatostatin receptor 3 agonist	Phase 2/3	https://conductscience.org/library/genes/6753	Drugs and targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01620138	Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas	Phase 2/3	21	2016-06-16	Non-functioning Pituitary Adenomas, Prolactinomas	CABERGOLINE, PASIREOTIDE	Its record names the disease	ClinicalTrials.gov
NCT01283542	Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.	Phase 2	20	2019-04-26	Non-functioning Pituitary Adenoma	PASIREOTIDE	Its record names the disease	ClinicalTrials.gov
NCT04335357	TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas	Phase 2	150		Non-Functional Pituitary Adenoma, Pituitary Tumor, Nonfunctioning	ONZIGOLIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02288962	Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas	Phase 3	60		Pituitary Neoplasms, Adenoma	CABERGOLINE	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Pasireotide vs Cabergoline: serious adverse events	0 of 12	0 of 9	21	NCT01620138

Source Trial comparisons

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0019613

GET https://conductscience.org/api/diseases/v1/MONDO_0019613/drugs

API reference For AI assistants